These results are in good agreement with those reported earlier by Levine and collaborators [39], who analyzed 373 endometrial carcinomas and found extensive copy number alterations, few DNA methylation changes, low estrogen receptor/progesterone receptor levels, and frequent POLE, TP53, PTEN, CTNNB1, PIK3CA, ARID1A, and KRAS mutations, plus novel mutations in the chromatin remodeling complex gene ARID5B (see also below). This evidence concerns the gene KRAS and endometrial carcinoma.